Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening

Transfusion

Volumn 43, Issue 10, 2003, Pages 1452-1459

  Tobler, Leslie H ^a   Stramer, Susan L ^b   Lee, Stephen R ^b   Masecar, Barbara L ^b   Peterson, Jon E ^b   Davis, E Anne ^b   Andrews, William E ^b   Brodsky, Jaye P ^b   Kleinman, Steven H ^b   Phelps, Bruce H ^b   Busch, Michael P ^b  

^a Blood Centers of the Pacific   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; HEPATITIS C ANTIBODY;

ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; ELECTROIMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCLEIC ACID AMPLIFICATION; PERFORMANCE; POLYMERASE CHAIN REACTION; SCREENING TEST; SEROCONVERSION; UNITED STATES; VIRUS DETECTION; BLOOD; ENZYME IMMUNOASSAY;

BLOOD DONORS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOENZYME TECHNIQUES; RNA, VIRAL;

EID: 0142040261     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00521.x     Document Type: Article

References (33)

1. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002;42:966-72.
2. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
3. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997;11:155-72.
4. Courouce AM, Pillonel J. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996;335:1609-10.
5. Barrera JM, Gil C, Ercilla G, et al. Earlier detection of anti-HCV seroconversion in post-transfusion NANBH by a prototype HCV 3.0 ELISA (abstract). Presented at International Symposium on Viral Hepatitis and Liver Disease. Tokyo 1993:72.
6. Simon N, Courouce AM, Lemarrec N, et al. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994;46:504-11.
7. Goffin E, Pirson Y, Cornu C, et al. Outcome of HCV infection after renal transplantation. Kidney Int 1994;45:551-5.
8. Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993;18:497-502.
9. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype lb) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-6.
10. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-82.
11. Kondili LA, Chionne P, Constantino A. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C infection in the general population. Gut 2002;50:693-6.
12. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
13. Luppa PB, Huber U, Rosenbrock H, et al. Evaluation of an enhanced chemiluminescence immunoassay for total serum testosterone using the Vitros ECi analyzer. J Clin Ligand Assay 2000;23:308-15.
14. Cha TA, Kolberg J, Irvine B, et al. Use of a signature nucleotide sequence of the hepatitis C virus for the detection of viral RNA in human serum and plasma. J Clin Microbiol 1991;29:2528-34.
15. Lee SR, Wood CL, Lane MJ, et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay. Transfusion 1995;35:845-9.
16. Gretch D. Diagnostic tests for hepatitis C. NIH Development Consensus Conference. Management of hepatitis C. Bethesda, MD: NIH, 1997:45-56.
17. Damen M, Zaaijer H, Cuypers HT, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995;33:745-9.
18. Dow BC, Buchanan I, Munro H, et al. Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors. J Med Virol 1996;49:132-6.
19. Makris K, Kouvelis V, Drakopoulos I, et al. Frequency and characteristics of post-transfusion hepatitis in Greece with emphasis on hepatitis C: comparing second- and third-generation assays. Trans Med 1995;5:213-24.
20. Courouce AM, Le Marrec N, Girault A, et al. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994;34:790-5.
21. Busch MP, Korelitz IJ, Kleinman SH. Declining value of aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C infection. Transfusion 1995;35:903-10.
22. Busch MP, Lee SR. Yield of HCV EIA 3.0 vs. 2.0 for detection of seroconverting donors (abstract). Transfusion 1996; 36(Suppl):51S.
23. Galel SA, Strong DM, Tegtmeier GE, et al. Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays. Transfusion 2002;42:1507-13.
24. Hitzler WE, Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion 2001;41:333-7.
25. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63.
26. Kao JH, Lai MY, Hwang YT, et al. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay. Dig Dis Sci 1996;41:161-5.
27. Vrielink H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 1997;37:845-9.
28. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCVin post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-8.
29. Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994;343:853-4.
30. Goffin E, Pirson Y, Cornu C, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994;343:854.
31. Uyttendaele S, Claeys H, Mertens W, et al. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994;66:122-9.
32. Psichogiou M, Katsoulidou A, Vaindirli E, et al. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study on Viral Hepatitis. Transfusion 1997;37:858-62.
33. Vernelen K, Claeys H, Verhaert H, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody (letter). Lancet 1994;343:853.